ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	1.89T
Revenue (ttm)	274.45B
Net Income (ttm)	29.52B
Shares Out	20.15M
EPS (ttm)	1,488.44
PE Ratio	62.95
Forward PE	37.96
Dividend	500.00 (0.55%)
Ex-Dividend Date	Dec 27, 2024

Volume	72,166
Average Volume	219,292
Open	93,500
Previous Close	93,700
Day's Range	92,150 - 94,200
52-Week Range	66,600 - 120,800
Beta	0.45
RSI	58.52
Earnings Date	Jul 25, 2025

About ST Pharm

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.